Cadila Pharmaceuticals Launches Rituximab and Bevacizumab Biosimilars

Goodwin
Contact

Goodwin

On July 29, 2020, Cadila Pharmaceuticals announced its launch of Rituximab biosimilar Ritucad for the Indian market.  Rituximab is used to treat certain types of blood cancers and rheumatoid arthritis.

 Ritucad was the Indian pharmaceutical company’s second biosimilar launch in July.  On July 22, 2020, Cadila announced the launch of Bevaro, a Bevacizumab biosimilar.  Bevacizumab is used to treat multiple cancers, including ovarian, cervical, breast, and lung cancer.

 Cadila reported that it is strengthening its biosimilar portfolio and intends to launch more biosimilar products in the future.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.